Related Experiment Video
Updated: Jan 23, 2026

Monitoring Lung Function with Electrical Impedance Tomography in the Intensive Care Unit
Published on: September 6, 2024
Diarrhea and patient outcomes in the intensive care unit: Systematic review and meta-analysis
Shunsuke Taito1, Yusuke Kawai2, Keibun Liu3
1Division of Rehabilitation, Department of Clinical Practice and Support, Hiroshima University Hospital, Hiroshima, Japan.
Purpose:
We aimed to determine whether diarrhea experienced by patients in the intensive care unit (ICU) is related to their clinical outcomes.
Material And Methods:
We performed a systematic review and meta-analysis. We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL, and the World Health Organization International Clinical Trials Registry Platform between inception and August 2018. The primary outcome was ICU mortality, and secondary outcomes included hospital mortality, ICU length of stay, hospital length of stay. The quality of evidence was determined using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.
Results:
Twelve studies (enrolling 13,140 patients) compared patients with diarrhea to patients without diarrhea in the ICU. Diarrhea was related to ICU mortality (relative risk [RR]: 1.43; 95% confidence interval [CI]: 1.03 to 1.98). The mean difference (MD) in ICU length of stay between patients with and without diarrhea was 8.08 days (95% CI: 5.85 to 10.32), while the MD in hospital length of stay was 9.67 (95% CI: 2.17 to 17.16). The certainty of evidence for these outcomes was low.
Conclusions:
The diarrhea experienced by patients may be associated with higher mortality and prolonged length of stay in the ICU and hospital.
More Related Videos
Related Concept Videos
Patient-centered Care
Measurement: Derived Units
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Measurement: Standard Units
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

